Tastekin F.Aksu K.2024-08-312024-08-3120241699-258Xhttps://doi.org/10.1016/j.reuma.2024.06.003https://hdl.handle.net/11454/103904In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD. © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatologíaen10.1016/j.reuma.2024.06.003info:eu-repo/semantics/closedAccessAdalimumabCalcium pyrophosphateChondrocalcinosisTumor necrosis factor-alphaArticle2-s2.0-85199130783Q3